Key Inclusion Criteria:

        Subjects may be enrolled in this study only if they satisfy all the following criteria
        (NOTE: This is not an exhaustive list):

          -  Subjects aged ≥18 years.

          -  ECOG performance status ≤ 2

          -  Subjects with advanced relapsed, refractory, or resistant hematological malignancies,
             as defined below:

          -  Subjects with documented IDH mutation per local or institutional next generation
             sequence (NGS).

          -  Subjects must be refractory to or intolerant of established therapies

        Key Exclusion Criteria:

        Subjects are not eligible for enrollment into this study if they meet any of the following
        criteria (NOTE: This is not an exhaustive list):

          -  Subjects who received an investigational agent <14 days prior to their first day of
             study drug administration

          -  Subjects who are pregnant or breastfeeding

          -  Subjects with an active severe infection, some treated infections and with an expected
             or with an unexplained fever >38.3°C during screening visits or on their first day of
             study drug administration.

          -  Subjects with some current or prior heart conditions

          -  Subjects taking medications that are known to prolong the QT interval may not be
             eligible

          -  Subjects with immediately life-threatening, severe complications of leukemia such as
             uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated
             intravascular coagulation

          -  Some subjects with some current or prior gastrointestinal or liver diseases

          -  Subjects with inadequate organ function as defined by the protocol